Clinical Trial Update: Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating safety and immunogenicity of multiple consistency lots and a high-dose lot of the rVSV-ZEBOV-GP Ebola vaccine in health…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Infection

Drugs mentioned

• rVSV-ZEBOV-GP (vesicular stomatitis virus-based Ebola vaccine (GP))

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Prevention of Ebola Infection | Phase 3 | Status: COMPLETED | Results posted: 2018-10-12